Tecentriq vs. Opdivo

Tecentriq (atezolizumab) and Opdivo (nivolumab) are monoclonal antibodies used to treat different types of cancer.

Tecentriq is used to treat patients with locally advanced or metastatic urothelial carcinoma (cancer) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Opdivo is used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; and to treat metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

Side effects of Tecentriq and Opdivo that are similar include fatigue, decreased appetite, nausea, vomiting, constipation, diarrhea, abdominal pain, fever, swelling of the extremities, joint pain, itching, rash, shortness of breath, and cough.

Side effects of Tecentriq that are different from Opdivo include urinary tract infection (UTI), back or neck pain, anemia, dehydration, intestinal obstruction, urinary obstruction, blood in urine, acute kidney injury, venous thromboembolism, severe infection (sepsis), and pneumonia.

Side effects of Opdivo that are different from Tecentriq include upper respiratory tract infection, muscle pain, weakness, chest pain, weight loss, irregular heartbeat, eye inflammation, infusion-related reactions, increased amylase, increased lipase, dizziness, numbness and tingling, skin peeling, skin redness, and psoriasis.

Both Tecentriq and Opdivo may interact with other drugs.

Common side effects of Tecentriq include:

• fatigue
• decreased appetite
• nausea
• vomiting
• constipation
• diarrhea
• abdominal pain
• urinary tract infection
• fever
• swelling of the extremities
• back or neck pain
• joint pain
• anemia
• dehydration
• itching
• rash
• intestinal obstruction
• urinary obstruction
• blood in the urine (hematuria)
• shortness of breath
• cough
• acute kidney injury
• venous thromboembolism
• severe infection (sepsis)
• pneumonia

Common side effects of Opdivo include:

• fatigue
• rash
• itching
• cough
• upper respiratory tract infection
• swelling of the extremities
• shortness of breath
• muscle pain
• decreased appetite
• nausea
• vomiting
• constipation
• diarrhea
• weakness
• swelling
• fever
• abdominal pain
• chest pain
• joint pain
• weight loss
• irregular heartbeat
• eye inflammation
• infusion-related reactions
• increased amylase
• increased lipase
• dizziness
• numbness and tingling
• skin peeling
• skin redness and
• psoriasis.

Tecentriq (atezolizumab) Injection for intravenous infusion is a monoclonal antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (cancer) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Opdivo (nivolumab) is a human monoclonal antibody used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; and to treat metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

Tecentriq may interact with other drugs. Tell your doctor all medications and supplements you use.

Opdivo may interact with other drugs. Tell your doctor all medications and supplements you use.

The recommended dose of Tecentriq is 1200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.

The recommended dose of Opdivo depends on the condition being treated and whether Opdivo is being administered as a single agent or in combination with another drug.